Gilteritinib is primarily used as a targeted therapy in the treatment of acute myeloid leukemia (AML), especially in patients who have tested positive for FLT3 mutations. It functions as a FLT3 inhibitor, blocking the activity of the FLT3 receptor tyrosine kinase, which when mutated, contributes to uncontrolled cell proliferation in leukemia. It is particularly effective in relapsed or refractory AML, offering a treatment option for patients who have not responded to prior therapies. Gilteritinib has shown improved response rates and survival outcomes in clinical trials, making it a valuable option in precision oncology. Its oral bioavailability allows for convenient administration compared to intravenous treatments.